Premium
High frequency of potential interactions between direct‐acting antivirals and concomitant therapy in HIV /hepatitis C virus‐coinfected patients in clinical practice
Author(s) -
Macías J,
Monge P,
Mancebo M,
Merchante N,
Neukam K,
Real LM,
Pineda JA
Publication year - 2017
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12471
Subject(s) - ombitasvir , paritaprevir , dasabuvir , medicine , ledipasvir , daclatasvir , simeprevir , sofosbuvir , coinfection , concomitant , genotype , ritonavir , virology , hepatitis c , hepatitis c virus , viral load , human immunodeficiency virus (hiv) , virus , ribavirin , antiretroviral therapy , biochemistry , chemistry , gene
The aim of the study was to analyse the frequency and degree of potential drug-drug interactions (DDIs) between direct-acting antivirals (DAAs) and concomitant medication used by HIV/hepatitis C virus (HCV)-coinfected patients, including antiretroviral therapy (ART) and other drugs.